Compare Stocks: MAZE, SRRK, MIRM, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$27.18 -1.8%	$27.79	$12.81 ▼ $53.65	$1.51B	2.21	352,009 shs	230,651 shs
MIRM Mirum Pharmaceuticals	$100.64 +1.9%	$110.91	$63.23 ▼ $130.00	$6.53B	0.52	755,791 shs	503,783 shs
SRRK Scholar Rock	$52.52 -1.0%	$50.80	$27.07 ▼ $58.49	$6.40B	0.69	1.05 million shs	496,597 shs
XENE Xenon Pharmaceuticals	$62.35 -2.9%	$61.34	$35.60 ▼ $72.66	$6.03B	0.62	643,940 shs	913,582 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-5.13%	+0.04%	+6.34%	+99.85%
MIRM Mirum Pharmaceuticals	0.00%	-0.01%	-14.25%	-1.51%	+54.50%
SRRK Scholar Rock	0.00%	-0.76%	+1.53%	+6.42%	+64.23%
XENE Xenon Pharmaceuticals	0.00%	-1.59%	-6.91%	+14.64%	+65.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$27.18 -1.8%	$27.79	$12.81 ▼ $53.65	$1.51B	2.21	352,009 shs	230,651 shs
MIRM Mirum Pharmaceuticals	$100.64 +1.9%	$110.91	$63.23 ▼ $130.00	$6.53B	0.52	755,791 shs	503,783 shs
SRRK Scholar Rock	$52.52 -1.0%	$50.80	$27.07 ▼ $58.49	$6.40B	0.69	1.05 million shs	496,597 shs
XENE Xenon Pharmaceuticals	$62.35 -2.9%	$61.34	$35.60 ▼ $72.66	$6.03B	0.62	643,940 shs	913,582 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-5.13%	+0.04%	+6.34%	+99.85%
MIRM Mirum Pharmaceuticals	0.00%	-0.01%	-14.25%	-1.51%	+54.50%
SRRK Scholar Rock	0.00%	-0.76%	+1.53%	+6.42%	+64.23%
XENE Xenon Pharmaceuticals	0.00%	-1.59%	-6.91%	+14.64%	+65.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MAZE Maze Therapeutics	3.00	Buy	$66.00	142.83% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	36.46% Upside
SRRK Scholar Rock	3.12	Buy	$57.71	9.89% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	23.71% Upside

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, MIRM, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/7/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$76.00
8/7/2026	SRRK Scholar Rock	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $60.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/6/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$123.00
8/6/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MAZE Maze Therapeutics	$167.50M	9.01	N/A	N/A	$8.16 per share	3.33
MIRM Mirum Pharmaceuticals	$521.31M	12.53	$0.05 per share	1,974.15	($0.16) per share	-629.00
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.08 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	803.65	N/A	N/A	$12.85 per share	4.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest MAZE, SRRK, MIRM, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MAZE Maze Therapeutics	0.09	18.31	17.88
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
SRRK Scholar Rock	0.77	7.02	8.64
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MAZE Maze Therapeutics	N/A
MIRM Mirum Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
MAZE Maze Therapeutics	5.30%
MIRM Mirum Pharmaceuticals	8.32%
SRRK Scholar Rock	10.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable
SRRK Scholar Rock	140	121.79 million	109.24 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

MAZE, SRRK, MIRM, and XENE Headlines

Recent News About These Companies

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

August 15 at 6:32 AM | marketbeat.com

Steven Gannon Sells 10,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

August 14 at 7:07 AM | insidertrades.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

August 14 at 2:28 AM | marketbeat.com

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

August 13 at 8:58 PM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock

August 13 at 5:07 PM | marketbeat.com

Q3 EPS Forecast for Xenon Pharmaceuticals Boosted by Analyst

August 13 at 1:28 AM | americanbankingnews.com

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

August 11, 2026 | seekingalpha.com

HC Wainwright Issues Positive Outlook for XENE Earnings

August 11, 2026 | marketbeat.com

Equities Analysts Set Expectations for XENE Q1 Earnings

August 10, 2026 | americanbankingnews.com

Brokers Issue Forecasts for XENE Q1 Earnings

August 10, 2026 | marketbeat.com

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

August 9, 2026 | marketbeat.com

Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

August 7, 2026 | zacks.com

California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

August 7, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals Q2 Loss Widens

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 6, 2026 | marketbeat.com

Xenon Reports Q2 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Xenon Pharma Q2 2026 earnings preview

August 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, SRRK, MIRM, and XENE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

$27.18 -0.49 (-1.77%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$27.21 +0.03 (+0.11%)

As of 08/14/2026 07:34 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$100.64 +1.87 (+1.89%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$100.70 +0.06 (+0.06%)

As of 08/14/2026 07:34 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Scholar Rock NASDAQ:SRRK

$52.52 -0.54 (-1.02%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$52.27 -0.25 (-0.48%)

As of 08/14/2026 07:36 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$62.35 -1.88 (-2.93%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$62.52 +0.17 (+0.27%)

As of 08/14/2026 07:34 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, MIRM, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, SRRK, MIRM, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, SRRK, MIRM, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, SRRK, MIRM, and XENE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Mirum Pharmaceuticals NASDAQ:MIRM

Scholar Rock NASDAQ:SRRK

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, SRRK, MIRM, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, SRRK, MIRM, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, SRRK, MIRM, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE, SRRK, MIRM, and XENE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Mirum Pharmaceuticals NASDAQ:MIRM

Scholar Rock NASDAQ:SRRK

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools